{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-002961","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2022-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.110048+00:00","generated_at":"2026-06-26T04:05:25.121728+00:00","sec_items":["1.01","2.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xenetic Biosciences in-licenses DNase oncology platform from CLS Therapeutics for $500K cash + 875K shares + milestones","bullets":["Upfront payment: $500K cash + 875,000 common shares (250,000 issued to OPKO per third-party obligation).","Milestone payments up to $13M per program in cash plus up to 950,000 additional shares for regulatory milestones.","Licensed platform includes systemic DNase (co-admin with chemo/IO) and DNase-armored CAR T therapies.","Xenetic plans Phase 1 study of lead asset in locally advanced or metastatic solid tumors.","Tiered royalties on net sales (mid-single to low-double digits); sublicense revenue share in mid-teens to low-double digits."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-002961","json":"https://secwatch.observer/filing/0001683168-22-002961.json","markdown":"https://secwatch.observer/filing/0001683168-22-002961.md","text":"https://secwatch.observer/filing/0001683168-22-002961.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316822002961/0001683168-22-002961-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316822002961/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T04:05:25.121728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}